BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 14502781)

  • 21. Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization.
    Cho EY; Choi YL; Han JJ; Kim KM; Oh YL
    Pathol Int; 2008 Jan; 58(1):17-25. PubMed ID: 18067636
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Investigation of HER2 overexpression in non-small cell lung cancer.
    Ugocsai K; Mándoky L; Tiszlavicz L; Molnár J
    Anticancer Res; 2005; 25(4):3061-6. PubMed ID: 16080566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of high copy number of HER2 associated with polysomy 17 on HER2 protein expression in invasive breast carcinoma.
    Shah SS; Wang Y; Tull J; Zhang S
    Diagn Mol Pathol; 2009 Mar; 18(1):30-3. PubMed ID: 19214111
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the clinical significance of HER2 amplification by chromogenic in situ hybridisation in patients with primary breast cancer.
    Dandachi N; Dietze O; Hauser-Kronberger C
    Anticancer Res; 2004; 24(4):2401-6. PubMed ID: 15330190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression.
    Umemura S; Takekoshi S; Suzuki Y; Saitoh Y; Tokuda Y; Osamura RY
    Oncol Rep; 2005 Aug; 14(2):337-43. PubMed ID: 16012712
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab.
    Dybdal N; Leiberman G; Anderson S; McCune B; Bajamonde A; Cohen RL; Mass RD; Sanders C; Press MF
    Breast Cancer Res Treat; 2005 Sep; 93(1):3-11. PubMed ID: 16184453
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HER2 amplification and overexpression is not present in pediatric osteosarcoma: a tissue microarray study.
    Somers GR; Ho M; Zielenska M; Squire JA; Thorner PS
    Pediatr Dev Pathol; 2005; 8(5):525-32. PubMed ID: 16211448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HER-2/neu analysis in breast cancer bone metastases.
    Zustin J; Boddin K; Tsourlakis MC; Burandt E; Mirlacher M; Jaenicke F; Izbicki J; Ruether W; Rueger JM; Bokemeyer C; Simon R; Sauter G
    J Clin Pathol; 2009 Jun; 62(6):542-6. PubMed ID: 19474354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.
    Ellis MJ; Tao Y; Young O; White S; Proia AD; Murray J; Renshaw L; Faratian D; Thomas J; Dowsett M; Krause A; Evans DB; Miller WR; Dixon JM
    J Clin Oncol; 2006 Jul; 24(19):3019-25. PubMed ID: 16754938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of HER2 gene status in breast cancer by chromogenic in situ hybridization: comparison with immunohistochemistry.
    Kounelis S; Kapranos N; Malamos N; Kouri-Bairaktari E
    Anticancer Res; 2005; 25(2A):939-46. PubMed ID: 15868931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of HER2 gene amplification detected by chromogenic in situ hybridization (CISH) in metastatic breast cancer.
    Todorović-Raković N; Jovanović D; Nesković-Konstantinović Z; Nikolić-Vukosavljević D
    Exp Mol Pathol; 2007 Jun; 82(3):262-8. PubMed ID: 17335803
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of Pathvysion and Poseidon HER2 FISH assays in measuring HER2 amplification in breast cancer: a validation study.
    Francz M; Egervari K; Kardos L; Toth J; Nemes Z; Szanto J; Szollosi Z
    J Clin Pathol; 2010 Apr; 63(4):341-6. PubMed ID: 19965795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
    Vinatzer U; Dampier B; Streubel B; Pacher M; Seewald MJ; Stratowa C; Kaserer K; Schreiber M
    Clin Cancer Res; 2005 Dec; 11(23):8348-57. PubMed ID: 16322295
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of Her2/neu, c-MYC and ZNF217 gene amplification during breast cancer progression using fluorescence in situ hybridization.
    Shimada M; Imura J; Kozaki T; Fujimori T; Asakawa S; Shimizu N; Kawaguchi R
    Oncol Rep; 2005 Apr; 13(4):633-41. PubMed ID: 15756435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry.
    Bilous M; Morey A; Armes J; Cummings M; Francis G
    Pathology; 2006 Apr; 38(2):120-4. PubMed ID: 16581651
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of HER2/neu in primary and metastatic breast cancer.
    Tuziak T; Olszewski WP; Olszewski W; Pieńkowski T
    Pol J Pathol; 2001; 52(1-2):21-6. PubMed ID: 11505677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
    Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B
    Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tyrosine1248-phosphorylated HER2 expression and HER2 gene amplification in female invasive ductal carcinomas.
    Taniyama K; Ishida K; Toda T; Motoshita J; Kuraoka K; Saito A; Tani Y; Uike T; Teramoto S; Koseki M
    Breast Cancer; 2008; 15(3):231-40. PubMed ID: 18264744
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome.
    Krüger S; Weitsch G; Büttner H; Matthiensen A; Böhmer T; Marquardt T; Sayk F; Feller AC; Böhle A
    Int J Oncol; 2002 Nov; 21(5):981-7. PubMed ID: 12370744
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas.
    Anninga JK; van de Vijver MJ; Cleton-Jansen AM; Kristel PM; Taminiau AH; Nooij M; Egeler RM; Hogendoorn PC
    Eur J Cancer; 2004 May; 40(7):963-70. PubMed ID: 15093570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.